Physician profile
Michelle Ying
NPI 1811079767
$7,410.43
in general payments reported to CMS, 2019-2025
31 companies · $1,134 in 2025
The $1,134 reported for 2025 was more than what 80% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,441 · 2020: $505 · 2021: $1,031 · 2022: $1,158 · 2023: $1,033 · 2024: $1,109 · 2025: $1,134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,275.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,540.72 | 2019-2025 | Clareon, Rocklatan, Rhopressa |
| Ocular Therapeutix, INC. | $621.03 | 2019-2025 | Dextenza |
| Sun Pharmaceutical Industries INC. | $550.76 | 2019-2025 | Cequa |
| Biotissue Holdings INC. | $513.54 | 2019-2025 | |
| Oyster Point Pharma, INC. | $510.28 | 2022-2024 | Tyrvaya, Ryzumvi |
| Abbvie INC. | $338.62 | 2022-2025 | Lumigan, Vuity, Alphagan P |
| Bausch & Lomb Americas INC. | $281.44 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Glaukos Corporation | $277.92 | 2020-2023 | |
| Kala Pharmaceuticals, INC. | $223.09 | 2019-2022 | |
| Dompe US, INC. | $209.22 | 2019-2025 | Oxervate |
| Johnson & Johnson Surgical Vision, INC. | $148.74 | 2019-2024 | Tecnis Iol |
| Novartis Pharmaceuticals Corporation | $146.88 | 2020-2023 | |
| Shire North American Group INC | $126.29 | 2019 | |
| Rayner Intraocular Lenses Limited | $109.04 | 2022-2024 | Omidria, Rayone Emv, Rayone Aspheric |
| Aerie Pharmaceuticals, INC. | $95.17 | 2019-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $90.13 | 2024-2025 | Vevye |
| Tarsus Pharmaceuticals, INC. | $89.65 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $86.02 | 2019-2021 | |
| Allergan, INC. | $85.17 | 2020-2022 | |
| Eyevance Pharmaceuticals LLC | $82.89 | 2019-2022 | |
| Horizon Therapeutics Plc | $56.86 | 2022-2023 | Tepezza |
| Omeros Corporation | $34.89 | 2019-2021 | |
| Apellis Pharmaceuticals, INC. | $26.01 | 2025 | Syfovre |
| Amgen INC. | $23.98 | 2024 | Tepezza |
| Rxsight INC | $23.70 | 2025 | Rxsight Injector Handpiece, Rxsight Injector Cartridge, Light Adjustable Lens (Lal) |
| Mallinckrodt Hospital Products INC. | $23.03 | 2025 | Acthar |
| Akorn, INC. | $22.62 | 2020 | |
| Carl Zeiss Meditec, INC. | $21.28 | 2019 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| New World Medical,INC. | $18.53 | 2022 | |
| Spinal Simplicity, LLC | $13.53 | 2023 | Ha Minuteman G3-R |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Ying listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.